Lannett gets FDA nod for generic butalbital, acetaminophen and caffeine capsules

Lannett has received the Food and Drug Administration’s clearance for butalbital, acetaminophen and caffeine, or BAC, capsules in two dosage strengths. 

The two dosage strengths of BAC capsules — 50 mg butalbital/300 mg acetaminophen /40 mg caffeine and 50 mg butalbital /325 mg acetaminophen/40 mg caffeine —  have a combined estimated market value of approximately $68.6 million for the 12 months ending October 2019, according to IQVIA.

"We have commenced marketing both dosage strengths of our newly approved BAC capsules," said Tim Crew, Lannett CEO.  "Thus far in fiscal 2020, we have launched about half a dozen products, among them are posaconazole, prednisone and cyproheptadine, and we expect to launch as many as 12 products in the coming six months."